Fintel reports that on December 12, 2024, Guggenheim downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Buy to Neutral. Analyst Price Forecast Suggests 1,981.80% Upside As of December 3 ...

WALTHAM, MA – Q32 Bio Inc., a pharmaceutical company specializing in the development of treatments for autoimmune diseases, has been notified by the Nasdaq Stock Market LLC of its noncompliance ...

WALTHAM, MA – Q32 Bio Inc., a pharmaceutical company specializing in the development of treatments for autoimmune diseases, has been notified by the Nasdaq Stock Market LLC of its noncompliance with ...

Earnings Estimate Revisions for Q32 Bio This gene editing company is expected to earn -$5.50 per share for the fiscal year ending December 2024, which represents a year-over-year change of 83.2%. ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a strict and lifelong gluten-free diet is currently the only treatment.

Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat autoimmune disease and cancer, today announces ...

Korro Bio, Q32 Bio, and Third Harmonic Bio) and one – Day Pone Biopharma – that chalked up its first product approval. "We're going to be disciplined, respect the math problem, and stick to ...

Story Feb. 10 - Q32 Bio: As part of a restructuring effort, the biotech is discontinuing a phase 2 trial and exploring strategic options for its tissue-targeted complement inhibitor platform ...

Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have earned an average rating of “Hold” from the eight analysts that are presently covering the firm, MarketBeat.com reports. Six analysts have ...